drugset / Trial / NCT04327973
Expanded Access for ATB200/AT2221 for the Treatment of IOPD
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cipaglucosidase alfa | Protein / enzyme biologic | — | — |
| Background | Miglustat | Small molecule | — | — |